Anal squamous cell carcinoma is a relatively uncommon disease that affects the tissues lining the anal canal and the area around the anus. Treatment typically focuses on controlling the tumor, preserving bowel function, and improving quality of life. While the disease was once mainly treated with surgery, modern approaches rely heavily on combining radiation and chemotherapy, often avoiding the need for major operations.
How Treatment Goals Are Defined for Anal Cancer
The main aim of treating anal squamous cell carcinoma is to eliminate the cancer cells while preserving the ability to control bowel movements and maintain a normal life. When the disease is caught early, doctors can often cure it completely. Treatment choices depend heavily on the size of the tumor, where it is located, whether it has spread to nearby lymph nodes or distant organs, and the patient’s overall health condition[1]. For tumors smaller than two centimeters, the outlook tends to be much better than for larger ones[10].
Healthcare providers follow established medical guidelines when deciding which treatment path to recommend. These guidelines are developed by expert panels and updated regularly based on research findings. Each treatment plan is tailored to the individual, taking into account not only the cancer itself but also the person’s ability to tolerate intensive therapies. Some patients may benefit from standard treatments that have been used successfully for decades, while others might be candidates for newer approaches being tested in research studies[3].
Because anal cancer often develops in a sensitive and functionally important part of the body, preserving the structure of the anus and rectum is a major priority. In the past, removing the anus completely and creating a permanent colostomy—a surgical opening in the abdomen for waste elimination—was the standard approach. Today, doctors can often avoid this outcome by using combinations of radiation and chemotherapy that shrink or destroy tumors without surgery[6][8].
Standard Treatment Approaches
The cornerstone of modern treatment for anal squamous cell carcinoma is a combination of radiation therapy and chemotherapy, often referred to as chemoradiation or chemoradiotherapy. This approach has remained remarkably consistent since it was first introduced in the 1970s. Before that time, nearly all patients with invasive anal cancer underwent a major surgery called abdominoperineal amputation, which removed the anus, rectum, and part of the bowel, requiring a permanent colostomy[6][17].
Radiation therapy uses high-energy beams to kill cancer cells. When delivered to the anal region, it targets the tumor and nearby areas where cancer might have spread. Chemotherapy involves using medicines that destroy rapidly dividing cells throughout the body. When these two treatments are given together, the chemotherapy makes the cancer cells more vulnerable to radiation, improving the overall effectiveness of the treatment[11][18].
The most commonly used chemotherapy drugs in this setting are 5-fluorouracil (often shortened to 5-FU) and mitomycin. According to widely followed clinical guidelines, 5-fluorouracil is typically given as a continuous infusion through a vein during the first four days of treatment, and then again during days 29 through 32. Mitomycin is administered as a quick injection on the first and 29th days[8]. Some treatment centers may substitute capecitabine, an oral medication, for 5-fluorouracil. Capecitabine is taken as pills twice daily for five days each week over a six-week period[8].
The radiation portion of treatment usually lasts between four and six weeks. Patients typically receive radiation five days per week, with weekends off to allow some recovery. The total duration of chemoradiation therapy can extend over several weeks, during which patients need frequent monitoring and supportive care[3][12].
There have been attempts to improve upon this regimen by substituting other chemotherapy drugs. One large clinical trial, known as RTOG 98-11, compared the standard combination of 5-fluorouracil with mitomycin against a combination of 5-fluorouracil with cisplatin, another cancer drug. The results showed that patients who received mitomycin had better outcomes: their five-year disease-free survival rate was nearly 68 percent, compared to about 58 percent for those who received cisplatin. Overall survival rates also favored the mitomycin group[8]. Because of these findings, the 5-fluorouracil and mitomycin combination remains the preferred standard approach.
Side effects from chemoradiation can be significant and affect daily life during treatment. Common problems include skin irritation and breakdown in the treatment area, diarrhea, fatigue, and discomfort during bowel movements. Managing these symptoms is a critical part of care. Patients may need medications to slow bowel movements, barrier creams to protect the skin, and strategies to maintain good hygiene such as sitz baths or gentle cleansing with water after using the toilet[8]. Some people also experience difficulty maintaining adequate nutrition during treatment and may benefit from dietary adjustments or nutritional supplements.
Surgery still plays a role in selected cases. For very small cancers that have not spread and are located at the anal margin—the outer edge of the anus—doctors may perform a local excision, which removes just the tumor and a small amount of surrounding healthy tissue. This is much less invasive than removing the entire anus and can often be done without requiring a colostomy[7][8].
When chemoradiation does not eliminate all the cancer, or if the cancer returns after initial treatment, more extensive surgery may become necessary. This typically involves abdominoperineal resection, during which the surgeon removes the anus, rectum, and part of the colon, and creates a permanent colostomy. This is now reserved mainly for cases where other treatments have not worked[11][18].
Innovative Treatments Being Studied in Clinical Trials
While the standard combination of radiation and chemotherapy has proven highly effective for many patients, researchers continue to explore new treatment options, particularly for people whose cancer does not respond to initial therapy or for those whose disease has spread to other parts of the body. Clinical trials test these new approaches to determine whether they are safe and whether they work better than existing treatments.
One of the most promising areas of research involves a class of drugs called immune checkpoint inhibitors. These medications work by helping the body’s own immune system recognize and attack cancer cells. Two drugs in this category, pembrolizumab and nivolumab, have entered clinical practice as second-line treatments for anal squamous cell carcinoma—meaning they are used when the first treatment has not worked or when cancer has returned[3][8].
Immune checkpoint inhibitors target specific proteins on immune cells or cancer cells that normally prevent the immune system from attacking. By blocking these proteins, the drugs essentially release the brakes on the immune response, allowing immune cells to fight the cancer more effectively. These treatments have shown promise in various types of cancer, and researchers are now studying their role in anal cancer more extensively. Because anal squamous cell carcinoma is often linked to human papillomavirus (HPV) infection, and because HPV-related cancers may be particularly responsive to immune-based therapies, there is hope that these drugs could significantly benefit patients[2][3].
Clinical trials for anal cancer typically proceed through several phases. Phase I trials focus mainly on safety, testing new drugs in small groups of patients to find the appropriate dose and to identify side effects. Phase II trials expand the study to more patients and begin to evaluate whether the treatment actually works against the cancer. Phase III trials compare the new treatment directly against the current standard treatment to determine which approach is better. Patients enrolled in these trials receive close monitoring and often gain access to cutting-edge therapies before they become widely available[3].
Researchers are also investigating modifications to the standard chemoradiation regimen. Some studies have tested whether giving chemotherapy before starting radiation and chemotherapy together—an approach called induction chemotherapy—might improve results. One trial, called ACCORD 03, examined this strategy but did not find clear benefits from adding the extra chemotherapy phase[8].
Another area of active research involves refining radiation techniques. Modern technologies allow doctors to deliver radiation more precisely to the tumor while minimizing exposure to surrounding healthy tissues. This may reduce side effects and allow higher radiation doses to be safely delivered to the cancer. Clinical trials are testing whether these advanced approaches lead to better outcomes for patients.
For patients with metastatic disease—meaning the cancer has spread to distant organs such as the liver or lungs—treatment options are more limited, and clinical trials become especially important. Standard chemoradiation is designed to treat cancer in and around the anal area, but it is not effective against cancer that has traveled elsewhere in the body. In these situations, doctors may use chemotherapy alone or combine it with immune checkpoint inhibitors. Ongoing trials are exploring the best ways to manage advanced disease and improve survival and quality of life[7].
Special Considerations for Certain Patient Groups
Some groups of patients require special attention when planning treatment for anal squamous cell carcinoma. People living with HIV—the virus that causes AIDS—have a higher risk of developing anal cancer because their weakened immune systems are less able to control HPV infection. These patients can still receive chemoradiation, but they may experience more severe side effects and may need adjustments to their HIV medications during cancer treatment. Close coordination between oncologists and infectious disease specialists is essential to manage both conditions effectively[1][3].
Similarly, people who are immunocompromised due to organ transplants or other medical conditions may face additional challenges during treatment. Their doctors must balance the need to treat the cancer aggressively with the need to avoid overwhelming an already vulnerable immune system.
Follow-Up Care and Monitoring After Treatment
After completing chemoradiation or surgery, patients require ongoing follow-up to monitor for any signs that the cancer has returned and to manage long-term side effects of treatment. Regular check-ups typically include physical examinations, imaging tests, and sometimes biopsies to confirm that the cancer is gone or to detect it early if it recurs[12][13].
During the first few years after treatment, visits to the doctor may occur every few months. As time goes on without any sign of cancer returning, the frequency of visits may decrease. Imaging tests such as CT scans or MRI may be used periodically to check the treatment area and nearby lymph nodes. Some patients may undergo procedures like anoscopy—where a doctor uses a small tube with a light to look inside the anal canal—to visually inspect the area[1].
Long-term side effects can include chronic bowel problems, sexual dysfunction, and skin changes in the treated area. Some people experience ongoing pain or discomfort, while others have difficulty controlling bowel movements. These issues can affect quality of life significantly, and patients should work with their healthcare team to find strategies to manage them. Support from specialized nurses, dietitians, and other healthcare professionals can be invaluable during recovery and beyond[13].
Most Common Treatment Methods
- Chemoradiation (Chemoradiotherapy)
- This is the primary treatment for most anal squamous cell carcinomas, combining radiation therapy with chemotherapy to maximize effectiveness while preserving the anus and avoiding surgery[11][18].
- 5-fluorouracil and mitomycin are the most commonly used chemotherapy drugs in combination with radiation over a period of four to six weeks[8].
- Capecitabine, an oral chemotherapy medication, may be used as an alternative to intravenous 5-fluorouracil[8].
- Immunotherapy
- Surgery
- Local excision may be performed for very small tumors at the anal margin, removing only the tumor and a small margin of healthy tissue[7][8].
- Abdominoperineal resection is reserved for cases where chemoradiation has not worked or cancer has returned, requiring removal of the anus, rectum, and part of the colon with creation of a permanent colostomy[11][18].
